Kevan Shokat

Ziyang Zhang

Charles Craik

Peter Rohweder

Daniel Green


Monoclonal antibody target engagement is controllable with the presence or absence of small molecule KRas G12C inhibitors

Hap10Bio technologies offer the promise of treating resistance to covalent inhibitors of oncoproteins

From the UCSF Laboratories of Charles Craik and Kevan Shokat, together with Ziyang Zhang and Peter Rohweder

(click pictures for bios and publication)